Astellas Pharma plans to introduce a performance-linked stock compensation\u5236\u5ea6 for domestic and international executives, with an expected start date in April 2026. The\u5236\u5ea6 aims to enhance corporate value and maximize long-term shareholder value. Details such as\u5236\u5ea6 specifics,\u5bfe\u8c61\u8005, trust types, and amounts are specified, with the\u5236\u5ea6 period from May 21, 2026, to the end of August 2029.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4503-20260515-02.pdf","jir_short_summary":"Astellas Pharma plans to introduce a performance-linked stock compensation\u5236\u5ea6 for domestic and international executives, with an expected start date in April 2026. The\u5236\u5ea6 aims to enhance corporate value and maximize long-term shareholder value. Details such as\u5236\u5ea6 specifics,\u5bfe\u8c61\u8005, trust types, and amounts are specified, with the\u5236\u5ea6 period from May 21, 2026, to the end of August 2029.","jir_summary":"### \u6982\u8981 of the\u5236\u5ea6\nAstellas Pharma will introduce two types of long-term incentive\u5236\u5ea6 for directors: BIP trust and ESOP trust. The\u5236\u5ea6 will commence in April 2026 and will operate over a three-year period from May 21, 2026, to the end of August 2029. The\u5236\u5ea6 aims to promote the enhancement of corporate and shareholder value and support long-term corporate growth. The total trust amount is approximately 6,944 million yen, with detailed provisions on trust\u5951\u7d04,\u5bfe\u8c61\u8005, and\u682a\u5f0f\u53d6\u5f97 methods.\n\n### \u5236\u5ea6\u306e\u8a73\u7d30\u3068\u904b\u7528\n\u5bfe\u8c61\u8005\u306f\u30012026\u5e744\u67081\u65e5\u6642\u70b9\u3067\u5728\u4efb\u3057\u3066\u3044\u308b\u5f79\u54e1\u304a\u3088\u3073\u56fd\u5185\u5916\u306e\u30b0\u30eb\u30fc\u30d7\u5e79\u90e8\u306b\u9650\u5b9a\u3055\u308c\u3001\u4fe1\u8a17\u306e\u7a2e\u985e\u306fBIP\u4fe1\u8a17\u3068ESOP\u4fe1\u8a17\u3067\u3059\u3002\u4fe1\u8a17\u91d1\u984d\u306f\u3001\u5f79\u54e1\u306e\u696d\u7e3e\u9023\u52d5\u6027\u3068\u682a\u5f0f\u53d6\u5f97\u8cc7\u91d1\u3068\u3057\u3066\u8a2d\u5b9a\u3055\u308c\u3001\u4fe1\u8a17\u5951\u7d04\u65e5\u306f2026\u5e745\u670821\u65e5\u3092\u4e88\u5b9a\u3057\u3066\u3044\u307e\u3059\u3002\u4fe1\u8a17\u306e\u671f\u9593\u306f3\u5e74\u9593\u3067\u3001\u682a\u5f0f\u306e\u53d6\u5f97\u65b9\u6cd5\u306f\u682a\u5f0f\u5e02\u5834\u304b\u3089\u306e\u53d6\u5f97\u3068\u898f\u5b9a\u3055\u308c\u3066\u304a\u308a\u3001\u4fe1\u8a17\u7d42\u4e86\u6642\u306b\u306f\u6b8b\u4f59\u8ca1\u7523\u306e\u53d6\u308a\u6271\u3044\u3084\u682a\u5f0f\u306e\u5e30\u5c5e\u306b\u3064\u3044\u3066\u3082\u898f\u5b9a\u3055\u308c\u3066\u3044\u307e\u3059\u3002","jir_financial_highlights":"Trust Amount: 561 million yen (planned) (unknown)\nTrust Amount (same as above): 6,383 million yen (planned) (unknown)\nTrust Contract Date: May 21, 2026 (planned) (unknown)","jir_category":"","jir_hashtags":"#AstellasPharma, #IR\u5236\u5ea6, #LongTermIncentive","jir_key_figures":"Trust amount total: 6,944 million yen (planned)\nTrust contract date: May 21, 2026 (planned)\n\u5236\u5ea6\u671f\u9593: May 21, 2026 \uff5e End of August 2029 (planned)","jir_meta_title":"\u3010Astellas Pharma\u3011Implementation of Long-Term Stock Reward\u5236\u5ea6\uff5cMay 2026","jir_meta_description":"Astellas Pharma introduces a long-term incentive\u5236\u5ea6 for directors, with a trust\u5951\u7d04 signed in May 2026. Details, amounts, and\u671f\u9593 are explained.","jir_og_title":"\u3010Astellas Pharma\u3011Implementation of Long-Term Stock Reward\u5236\u5ea6\uff5cMay 2026","jir_og_description":"Astellas Pharma will introduce a long-term incentive\u5236\u5ea6 for directors in May 2026. Detailed information on\u5236\u5ea6\u5185\u5bb9 and trust\u91d1\u984d.","jir_og_image_url":"\/assets\/og\/company-corporate_restructuring.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-51848","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n